Canadian Sciences Speakers Network

Réseau Canadien de Panélistes Scientifiques


Imogen R. Coe: Profile Photo

Imogen R. Coe

Toronto, Ontario

Position: Professor

Organization: Toronto Metropolitan University

Dr. Imogen R. Coe is a professor of Chemistry and Biology at Toronto Metropolitan University (TMU) and an affiliate scientist at St. Michael’s Hospital in Toronto. She is an active researcher and former academic leader, being the founding dean of the Faculty of Science at TMU. Dr. Coe is also an award-winning scholar-activist in Canada with respect to the integration of principles of inclusion, diversity, equity and accessibility (IDEA) into research cultures in science.

Areas of Expertise:

+ Membrane Transport Proteins, Pharmacology, Novel therapeutics
+ EDI in research and organizational cultures in science, engineering and medicine

Language(s):

+ English


My Work

What I do:

I am an academic research scientist working on how things get in and out of cells – particularly drugs – but also the cellular biology and impact of innovative therapeutics using techniques like ultrasound and micro/nano-bubbles. In parallel, I have extensive experience and expertise relating to the integration of principles of equity, diversity, inclusion, accessibility and cultural competencies in research cultures in science, medicine and engineering.

Ask me about:

How to integrate EDI (or DEI, IDEA, etc.) into your research organization or funding body or your research proposal, academic division or science culture.

Why me:

I have extensive experience as a biomedical academic researcher, former academic leader and scholar-activist. If you want to know more about how to create inclusive cultures in science or research and how to work with policy-makers to support science and research, then I have years of experience and an engaging way to help individuals and groups (departments, programs, science societies, etc.) understand and implement EDI&A principles into their research to effective positive change, increased innovation and outputs.


About Me

Sector: Academia (Post Secondary)

English proficiency: Read, Write, Speak

Title: Dr.

Pronouns: She/Her/Hers

Gender: Female

Demographic: European / White


Recent Publications

Title Year
Characterization of equilibrative nucleoside transport of the pancreatic cancer cell line: Panc-12023
Inclusion, diversity, equity, and accessibility: From organizational responsibility to leadership competency2021
The complex chemistry of diversity and inclusion: a 30-year synthesis2021
Dosage-controlled intracellular delivery mediated by acoustofluidics for lab on a chip applications2021
An ultrafast enzyme-free acoustic technique for detaching adhered cells in microchannels2021
So, you want to host an inclusive and accessible conference?2021
Enacting workplace culture change for excellence in research: a gender lens2020
Oligomerization of equilibrative nucleoside transporters: a novel regulatory and functional mechanism involving PKC and PP12018
Rapamycin-inspired macrocycles with new target specificity2018
Analysis of the cytotoxic effects of combined ultrasound, microbubble and nucleoside analog combinations on pancreatic cells in vitro2018
Extended exposure to substrate regulates the human equilibrative nucleoside transporter 1 (hENT1)2016
The Life and Contributions of Countess Ada Lovelace: Unintended Consequences of Exclusion, Prejudice, and Stereotyping2016
N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function2016
Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir2016
Novel regulation of equlibrative nucleoside transporter 1 (ENT1) by receptor-stimulated Ca2+-dependent calmodulin binding2016
Abstract 3788: Contributions of novel nuclear nucleoside transporters, HNP36 and HNP32, to DNA synthesis during cell cycle2015
N-linked Glycosylation of human SLC1A5 (ASCT2) transporter is critical for trafficking to membrane2015
Persistent Hepatitis C Virus Infection Impairs Ribavirin Antiviral Activity through Clathrin-Mediated Trafficking of Equilibrative Nucleoside Transporter 12014
Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice2014
Steroid hormones are novel nucleoside transport inhibitors by competition with nucleosides for their transporters2013
The adenosine transporter, ENT1, in cardiomyocytes is sensitive to inhibition by ethanol in a kinase-dependent manner: implications for ethanol-dependent cardioprotection and nucleoside analog drug cytotoxicity2013
Absence of equilibrative nucleoside transporter 1 in ENT1 knockout mice leads to altered nucleoside levels following hypoxic challenge2011
The Equilibrative Nucleoside Transporter (ENT1) can be phosphorylated at multiple sites by PKC and PKA2011
Analysis of recombinant tagged equilibrative nucleoside transporter 1 (ENT1) expressed inE. coliThis paper is one of a selection of papers published in a Special Issue entitled CSBMCB 53rd Annual Meeting — Membrane Proteins in Health and Disease, and has undergone the Journal’s usual peer review process.2011
The life cycle of human equilibrative nucleoside transporter 1: From ER export to degradation2011